- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01567930
Temsirolimus as Second-line Therapy in HCC
A Phase II Study of Temsirolimus as Second-line Therapy in Patients With Advanced, Unresectable Hepatocellular Carcinoma
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
Currently, no standard therapy exists for patients who progress on sorafenib. mTOR signaling is often up-regulated in HCC promoting cell growth and survival. This process is inhibited by rapamycin, a specific inhibitor of mTOR. Temsirolimus, a rapamycin analog, may delay tumor progression by inhibiting mTOR in HCC.Intervention: Temsirolimus IV
Eligible patients will receive temsirolimus IV on days 1,8,15 every 21 days. Treatment will continue till disease progression or untolerable side effects
Tipo de estudo
Inscrição (Antecipado)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
Tennessee
-
Memphis, Tennessee, Estados Unidos, 38120
- Recrutamento
- Boston Baskin Cancer Foundation
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
Patients must have advanced unresectable or metastatic hepatocellular carcinoma (HCC). Prior diagnosis of HCC could have been established histologically or based on one of the following criteria:
- Liver mass > 2cm: Characteristic enhancement on at least one imaging technique(triphasic CT scan, MRI, or contrast enhanced ultrasound) or AFP > 200 ng/ml.
- Liver mass between 1 and 2 cm: Characteristic enhancement on two imaging techniques.Diagnosis of HCC must have been confirmed by biopsy if non-characteristic enhancement on imaging.
- All patients must have received exactly one prior systemic therapy (cytotoxic chemotherapy or targeted therapies) and must not be eligible for further locoregional treatment modalities.
- All patients must have measurable disease per RECIST criteria.
- Patients with previous locoregional therapies, including but not limited to radio-frequency ablation, cryoablation, percutaneous ethanol injection, chemo-embolization, hepatic artery embolization, and hepatic artery infused FUDR, stereotactic radiotherapy are eligible provided they have documented progression of their disease or have measurable extrahepatic disease.
- Patients must have an ECOG performance status of 0 - 2 (see Appendix B).
- Patients must be greater than or equal to 18 years of age.
- Patients with Child-Pugh class A (score of 5-6) or class B (score of 7-9) are eligible.
Patients must have adequate organ function as defined by:
- AST, ALT and Alkaline phosphatase ≤ 5x upper limit of normal (ULN)
- Total Bilirubin < 2 mg/dl.
- Creatinine clearance ≥ 15ml/min & patients must not be dialysis dependent.
Patients must have adequate bone marrow function as defined by:
- Leukocytes ≥ 2000 / mm3 or absolute neutrophil count (ANC) ≥ 1000 / mm3
- Platelet count ≥ 75000 / mm3
- Pregnant and nursing women will be excluded from this study. All patients of reproductive potential must agree to use adequate birth control measures to be eligible for study enrollment.
- Prior palliative radiotherapy is permissible provided it has been completed at least 2 weeks prior to study entry and the patient has recovered from any radiation-related side effects.
- Patients must not be receiving any other investigational agents or other anti-cancer therapies. At least 28 days must have elapsed since completion of previous systemic therapy prior to study entry and the patient should have recovered from all toxicities related to prior therapy.
- Patients must not have a history of other malignancies that are active and require therapy (other than non-melanoma skin cancers).
Exclusion Criteria:
- Patients with prior treatment with any mTOR inhibitor are not eligible.
- Patients with a history of an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris,cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements are not eligible.
- Patients taking cytochrome P450 enzyme-inducers or inhibitors are not eligible.
- Patients with a known history of HIV infection are not eligible.
- Patients with uncontrolled hyperlipidemia or hypercholesterolemia are not eligible (fasting serum cholesterol > 350 mg/dL or fasting serum triglycerides > 400 mg/dL).
- Patients with a known history or clinical evidence of CNS metastases are not eligible.
- Patients who, in the best judgment of the investigator, will not be able to comply with the requirements of the protocol are not eligible.
Patients with Child-Pugh class C liver disease are not eligible.
-
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
---|---|
Disease Progression
|
The primary outcome measure is to determine the proportion of patients who are progression free at 3 months.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
---|---|
Response rate
|
Response rate, clinical benefit rate (complete + partial response + stable disease > 12 weeks) and overall survival with temsirolimus
|
Safety and tolerability
|
Number and frequency of adverse events and serious adverse events will be monitored.
|
Biochemical response
|
Biochemical response (>50% decline in AFP levels from baseline) with temsirolimus
|
Pharmacokinetics
|
Pharmacokinetics will be assessed: AUC pre-dose, 1, 3, 24,48, 72 and 162 hours post dose.
|
Circulating tumor cells levels
|
Feasibility and utility of circulating tumor cells in this patient population
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Jasgit Sachdev, MD, University of Tennessee Cancer Institute
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças do aparelho digestivo
- Neoplasias por Tipo Histológico
- Neoplasias
- Neoplasias por local
- Adenocarcinoma
- Neoplasias Glandulares e Epiteliais
- Neoplasias do Aparelho Digestivo
- Doenças do Fígado
- Neoplasias Hepáticas
- Carcinoma
- Carcinoma Hepatocelular
- Efeitos Fisiológicos das Drogas
- Agentes Anti-Infecciosos
- Agentes Antineoplásicos
- Agentes imunossupressores
- Fatores imunológicos
- Agentes antibacterianos
- Antibióticos, Antineoplásicos
- Antifúngicos
- Sirolimo
Outros números de identificação do estudo
- 3066K1-2247
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .